Abstract:Despite recent therapeutic advances, achieving optimal glycaemic control remains a challenge in managing Type 2 Diabetes (T2D). Sodium-glucose co-transporter type 2 (SGLT2) inhibitors have emerged as effective treatments by promoting urinary glucose excretion. However, the full scope of their mechanisms extends beyond glycaemic control. At present, their immunometabolic effects remain elusive. To investigate the effects of SGLT2 inhibition or deletion, we compared the metabolic and immune phenotype between high fat diet-fed control, chronically dapagliflozin-treated mice and total-body SGLT2/ knockout mice. SGLT2 null mice exhibited superior glucose tolerance and insulin sensitivity compared to control or dapagliflozin-treated mice, independent of glycosuria and body weight. Moreover, SGLT2 null mice demonstrated physiological regulation of corticosterone secretion, with lowered morning levels compared to control mice. Systemic cytokine profiling also unveiled significant alterations in inflammatory mediators, particularly interleukin 6 (IL-6). Furthermore, unbiased proteomic analysis demonstrated downregulation of acute-phase proteins and upregulation of glutathione-related proteins, suggesting a role in the modulation of antioxidant responses. Conversely, IL-6 increased SGLT2 expression in kidney HK2 cells suggesting a role for cytokines in the effects of hyperglycemia. Collectively, our study elucidates a potential interplay between SGLT2 activity, immune modulation, and metabolic homeostasis.

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to explore the effect of SGLT2 (sodium - glucose cotransporter 2) inhibition or deletion on cortisol secretion in high - fat - diet mice and to explore its association with cytokine levels. Specifically, the researchers evaluated the impact of SGLT2 inhibition or deletion on metabolic and immune phenotypes by comparing high - fat - diet - fed mice, mice treated with dapagliflozin for a long time, and mice with systemic SGLT2 gene knockout, with particular attention to changes in cortisol regulation and cytokines. ### Main research questions: 1. **Effect of SGLT2 inhibition or deletion on metabolism**: The researchers wanted to know whether SGLT2 inhibition or deletion could improve glucose tolerance and insulin sensitivity in high - fat - diet mice and whether these effects were independent of urinary glucose levels and body weight changes. 2. **Effect of SGLT2 inhibition or deletion on cortisol secretion**: The researchers hoped to explore whether SGLT2 inhibition or deletion could regulate the physiological secretion pattern of cortisol, especially the cortisol levels in the morning and evening. 3. **Effect of SGLT2 inhibition or deletion on cytokine levels**: The researchers also hoped to understand whether SGLT2 inhibition or deletion would affect the circulating cytokine levels, especially the levels of inflammatory mediators such as IL - 6. ### Research background: - **Challenges in diabetes management**: Although significant progress has been made in diabetes treatment in recent years, achieving optimal blood - glucose control remains a challenge. SGLT2 inhibitors have become effective treatment methods by promoting urinary glucose excretion, but their mechanisms are not limited to blood - glucose control, and their immunometabolic effects are still unclear. - **Role of SGLT2**: SGLT2 is mainly expressed in the renal cortex. SGLT2 inhibitors (such as dapagliflozin) reduce blood - glucose levels by blocking SGLT2 activity on the early proximal membrane of renal tubules and reducing glucose reabsorption. In addition, SGLT2 inhibitors have also been found to have a wide range of pleiotropic effects, including effects on immunomodulation. ### Research methods: - **Animal model**: C57BL/6J mice were used and divided into three groups: control group, dapagliflozin - treated group, and SGLT2 gene - knockout group. All mice were fed a high - fat diet. - **Experimental design**: Glucose tolerance test, insulin tolerance test, urinary glucose and creatinine measurement, cytokine quantitative analysis, proteomics analysis, etc. were carried out. - **Molecular biology techniques**: Including RNA extraction, cDNA synthesis, qPCR, ELISA, LC - MS/MS, etc. ### Main findings: - **Metabolic advantages of SGLT2 gene - knockout mice**: SGLT2 gene - knockout mice showed better glucose tolerance and insulin sensitivity, and this effect was independent of urinary glucose levels and body weight changes. - **Normalization of cortisol secretion**: The cortisol secretion pattern of SGLT2 gene - knockout mice was more in line with physiological rules, with lower cortisol levels in the morning and higher cortisol levels in the evening. - **Changes in cytokine levels**: The IL - 6 level in SGLT2 gene - knockout mice was significantly decreased, while the levels of anti - inflammatory cytokines IL - 10 and FGF21 were significantly increased. - **Proteomics analysis**: The expressions of acute - phase proteins and glutathione - related proteins in SGLT2 gene - knockout mice were changed, suggesting their role in antioxidant response. ### Conclusion: This study revealed the potential interactions among SGLT2 activity, immunomodulation, and metabolic homeostasis, emphasizing the important role of SGLT2 in immune response and metabolic regulation.

Effects of SGLT2 Ablation or Inhibition on Corticosterone Secretion in High-Fat-Fed Mice: Exploring a Nexus with Cytokine Levels

SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function

Sodium glucose co-transporter 2 inhibition reduces succinate levels in diabetic mice

The effect of canagliflozin on gut microbiota and metabolites in type 2 diabetic mice

Effect of SGLT2 Inhibition on the transcriptomic and proteomic profile of non-diabetic Dahl SS Rats

Characterizing Murine Diabetic Glucose Metabolism Under Conditions of Attenuated Renal Glucose Reabsorption

SGLT1 Inhibition Attenuates Apoptosis in Diabetic Cardiomyopathy Via the JNK and P38 Pathway

Abstract 14007: Sodium-Dependent Glucose Transporters 2 Inhibition Ameliorates Obesity-Induced Metabolic Changes and Cardiomyopathy

Sodium Glucose Cotransporter 2 Inhibitor Dapagliflozin Depressed Adiposity and Ameliorated Hepatic Steatosis in High-Fat Diet Induced Obese Mice.

OS 17-03 ENHANCED SGLT2 FUNCTION REDUCES NATRIURESIS IN DIABETIC MICE

Dapagliflozin Ameliorates Ovulation Disorders via Attenuating Activated Microglia-Mediated Hypothalamic Inflammation in HFD-Fed Mice

Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease

Abstract P3149: Effect Of SGLT2 Inhibitors On Atrial Fibrillation Susceptibility In Diabetic Mice

Sodium–glucose cotransporter 2 inhibition suppresses HIF-1α-mediated metabolic switch from lipid oxidation to glycolysis in kidney tubule cells of diabetic mice

Sodium-Glucose Cotransporter 2 Inhibitor and a Low Carbohydrate Diet Affect Gluconeogenesis and Glycogen Content Differently in the Kidney and the Liver of Non-Diabetic Mice

Sodium-glucose cotransporter 2 inhibitors ameliorate ER stress-induced pro-inflammatory cytokine expression by inhibiting CD36 in NAFLD progression in vitro

Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/ SIRT1 Pathway

Effects of Canagliflozin on Weight Loss in High-Fat Diet-Induced Obese Mice.

Targeting Inflammatory Signaling Pathways with SGLT2 Inhibitors: Insights into Cardiovascular Health and Cardiac Cell Improvement

Inhibition of the sodium–glucose co‐transporter SGLT2 by canagliflozin ameliorates diet‐induced obesity by increasing intra‐adipose sympathetic innervation

Metabolic Communication by SGLT2 Inhibition